683 Capital Management Acquires IN8bio Inc Shares for Strategic Growth

683 Capital Management acquired 770,445 shares of IN8bio Inc at $1.55 per share, marking a strategic move by the firm into the biotechnology sector. The acquisition represents 0.06% of the firm's portfolio and 7.86% of its holdings in the traded stock, with the stock price increasing by 56.77% since the purchase. IN8bio Inc is a clinical-stage biopharmaceutical company specializing in cancer treatment, with a market capitalization of $23.719 million and a GF Score of 34/100, indicating poor future performance potential. The company faces challenges in profitability and growth, as reflected in its low ranks in these areas.